TNFRSF8 and lymphoma: Phase 2 trials of BV are ongoing, in the frontline with rituximab as a chemotherapy free regimen for CD30+ and/or EBV+ Lymphomas [NCT01805037], as consolidation after induction with CHEP-BV in patients with CD30-positive PTCL [NCT03113500] and as a single agent in R/R CD30 Low (<10%) mature T cell lymphoma [NCT02588651].